Cumberland Pharmaceuticals dismisses FORVIS as auditor, appoints CRI for FY2023

CUMBERLAND PHARMACEUTICALS INC

Effective May 18, 2023, dismissed FORVIS as independent auditor; new auditor is Carr, Riggs & Ingram (CRI) subject to engagement letter.
No disagreements on accounting principles, financial statement disclosure, or audit scope during 2021-2022 and interim 2023.
FORVIS audit reports for 2021 and 2022 were unqualified, no adverse opinion or modification.
Company provided FORVIS with disclosures; FORVIS furnished letter to SEC agreeing with statements (Exhibit 16.1).
No consultations with CRI regarding accounting principles or disagreements prior to appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.